(Albany, US) DelveInsight has launched a new report on “Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hyperuricemia-market
Scope of the Report
Hyperuricemia occurs when there’s too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.
Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:
Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren’t eliminating it quickly enough.
Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body’s defensive white blood cells may attack the crystals, causing inflammation and pain.
Rates of hyperuricemia have risen sharply since 1960.
The major players covered in the hyperuricemia drugs market are:
Table of Contents:
1. Key Insights
2. Executive Summary of Hyperuricemia
3. Competitive Intelligence Analysis for Hyperuricemia
4. Hyperuricemia: Market Overview at a Glance
4.1. Hyperuricemia Total Market Share (%) Distribution in 2017
4.2. Hyperuricemia Total Market Share (%) Distribution in 2030
5. Hyperuricemia: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hyperuricemia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hyperuricemia Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Hyperuricemia Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hyperuricemia Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Hyperuricemia Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Hyperuricemia Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Hyperuricemia Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hyperuricemia Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Hyperuricemia Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hyperuricemia Treatment and Management
8.2. Hyperuricemia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hyperuricemia Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Hyperuricemia: Seven Major Market Analysis
13.1. Key Findings
13.2. Hyperuricemia Market Size in 7MM
13.3. Hyperuricemia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hyperuricemia Total Market Size in the United States
15.1.2. Hyperuricemia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hyperuricemia Total Market Size in Germany
15.3.2. Hyperuricemia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hyperuricemia Total Market Size in France
15.4.2. Hyperuricemia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hyperuricemia Total Market Size in Italy
15.5.2. Hyperuricemia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hyperuricemia Total Market Size in Spain
15.6.2. Hyperuricemia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hyperuricemia Total Market Size in the United Kingdom
15.7.2. Hyperuricemia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hyperuricemia Total Market Size in Japan
15.8.3. Hyperuricemia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hyperuricemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=Pressrelease&utm_medium=Pressrelease&utm_campaign=Pressrelease